Drug Profile
Zanidatamab - BeiGene/Jazz Pharmaceuticals Inc/Zymeworks
Alternative Names: JZP-598; Zani - BeiGene/Jazz Pharmaceuticals Inc/Zymeworks; ZW 25Latest Information Update: 03 Apr 2024
Price :
$50
*
At a glance
- Originator Zymeworks
- Developer ALX Oncology; BeiGene; Jazz Pharmaceuticals Inc; Zymeworks
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; ERBB 2 receptor antagonists; Phagocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preregistration Biliary cancer
- Phase III Colorectal cancer; Gastric cancer; Oesophageal cancer
- Phase II Endometrial cancer; HER2 positive breast cancer
- Phase I/II Solid tumours
- No development reported Ovarian cancer
Most Recent Events
- 02 Apr 2024 Jazz Pharmaceuticals completes rolling BLA for Biliary cancer
- 08 Mar 2024 Zymeworks completes phase-II ZW25-IST-2 trial in Endometrial cancer (Late-stage disease, Second-line therapy or greater, Recurrent) in USA (IV) (NCT04513665)
- 06 Mar 2024 BeiGene announces intention to file BLA for zanidatamab with the NMPA for Biliary tract cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China during the second half of 2024